J&J reports Q3 2026 results, raises full-year sales and EPS guidance
Johnson & Johnson posted 5.9% reported sales growth to $25.4 billion and raised its 2026 outlook, citing regulatory and clinical progress across its portfolio.
SEC filing
Latest
1 story